- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
6
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
6 companies
Camurus
Market Cap: SEK 37.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 622.00
7D
3.4%
1Y
-2.1%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 225.20
7D
1.2%
1Y
-26.4%
BioArctic
Market Cap: SEK 28.3b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 319.00
7D
1.2%
1Y
45.0%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.82
7D
3.8%
1Y
-26.9%
Moberg Pharma
Market Cap: SEK 524.5m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 11.16
7D
16.7%
1Y
26.1%
AlzeCure Pharma
Market Cap: SEK 943.2m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.84
7D
8.6%
1Y
68.9%